ADAP News and Press, Adaptimmune Therapeutics plc From 04/01/19

PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting from its next generation SPEAR T-cell targeting MAGE-A4. T...

Adaptimmune Therapeutics plc (ADAP) Q4 2018 Results Earnings Conference Call February 27, 2019 08:00 PM ET Company Participants Juli Miller - IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - President, Research and Develo...

PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases ...

Adaptimmune ( ADAP ) Q4 results : Revenues: $1.5M (-65.1%). More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Earnings news and commentary, Read more ...

Adaptimmune (NASDAQ: ADAP ): Q4 GAAP EPS of -$0.06 misses by $0.01 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study - - Treating patients in expansio...

PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update before the U.S. ma...

Quick Take TCR2 Therapeutics ( TCRR ) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing therapies that harness the patient's immune system to fight cancer irrespective of human leukocyte antigens [HLA] sub...

PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in pati...

(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...